GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0

作者：

Coates, L. C. ^{[1
]}

Ritchlin, C. T. ^{[2
]}

Gossec, L. ^{[3
]}

Helliwell, P. ^{[4
]}

Rahman, P. ^{[5
]}

Hsia, E. C. ^{[6
,7
]}

Kollmeier, A. ^{[8
]}

Xu, X. L. ^{[8
]}

Karyekar, C. ^{[9
]}

Shawi, M. ^{[9
]}

Noel, W. ^{[10
]}

Jiang, Y. ^{[11
]}

Sheng, S. ^{[11
]}

Wang, Y. ^{[11
]}

Mease, P. J. ^{[12
,13
]}

机构：

[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

[2] Univ Rochester, Med Ctr, Dept Med AllergyImmunol & Rheumatol, Rochester, NY 14642 USA

[3] Sorbonne Univ, Rheumatol, Paris, France

[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[5] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada

[6] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[7] Univ Penn, Rheumatol, Philadelphia, PA 19104 USA

[8] Janssen Res & Dev LLC, Immunol, La Jolla, CA USA

[9] Janssen Res & Dev LLC, Immunol, Horsham, PA USA

[10] Janssen Res & Dev LLC, Immunol, Brussels, Belgium

[11] Janssen Res & Dev LLC, Biostat, Spring House, PA USA

[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[13] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.167

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS1024

引用

页码：781 / 782

页数：2

共 50 条

[41] Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Mease, Philip J.
van der Heijde, Desiree
Landewe, Robert B. M.
Mpofu, Shephard
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Bottcher, Elke
Navarra, Sandra V.
Zhu, Xuan
Readie, Aimee
Pricop, Luminita
Abrams, Ken
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[42] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL
Mease, P. J.
Kavanaugh, A.
Reimold, A.
Tahir, H.
Rech, J.
Hall, S.
Geusens, P.
Pascale, P.
Delicha, E. M.
Pricop, L.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 952 - 953
[43] GUSELKUMAB EFFICACY IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BY BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
Deodhar, Atul
Mease, Philip J.
Boencke, Wolf-Henning
Tesser, John
Schiopu, Elena
Chakravarty, Soumya D.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Shawi, May
Jiang, Yusang
Sheng, Shihong
Agarwal, Prasheen
Merola, Joseph F.
McInnes, Iain B.
Ritchlin, Christopher T.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S108 - S109
[44] Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Deodhar, Atul
Mease, Philip
Boehncke, Wolf-Henning
Tesser, John
Schiopu, Elena
Chakravarty, Soumya
Kollmeier, Alexa
Hsia, Elizabeth
Xu, Xie
Shawi, May
Jiang, Yusang
Sheng, Shihong
Agarwal, Prasheen
Merola, Joseph
McInnes, Iain
Ritchlin, Christopher
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[45] Efficacy and Safety of Guselkumab, an Interleukin-23p 19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
McInnes, Iain B.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Chakravarty, Soumya D.
Xu, Xie L.
Subramanian, Ramanand A.
Agarwal, Prasheen
Sheng, Shihong
Jiang, Yusang
Zhou, Bei
Zhuang, Yanli
van Der Heijde, Desiree
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (04) : 604 - 616
[46] Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
Mcinnes, Iain B.
Sewerin, Philipp
Sharaf, Mohamed
Efficace, Michela
Lavie, Frederic
Zimmermann, Miriam
Coates, Laura C.
RMD OPEN, 2024, 10 (04):
[47] Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naive patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study
Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf-Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Shawi, May
Yang, Ya-Wen
Sheng, Shihong
Agarwal, Prasheen
Helliwell, Philip S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB163 - AB163
[48] Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
Mease, Philip J.
Helliwell, Philip S.
Gladman, Dafna D.
Poddubnyy, Denis
Baraliakos, Xenofon
Chakravarty, Soumya D.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Sweet, Kristen
Shawi, May
Karyekar, Chetan S.
Deodhar, Atul
van der Heijde, Desiree
LANCET RHEUMATOLOGY, 2021, 3 (10): : E715 - E723
[49] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients With Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results From a Phase 3B Trial
McInnes, Iain
Sewerin, Philipp
Richard, Nicolas
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 80 - 80
[50] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
McInnes, Iain B.
Sewerin, Philipp
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4241 - 4244

← 1 2 3 4 5 →